By inhibiting key molecules involved in critical signaling pathways, such as the HER2 receptor in breast cancer or the BRAF protein in melanoma, targeted therapies can effectively suppress tumor growth and reduce the risk of relapse [383, 384]. The gene discussed is BRAF; the disease is neoplasm.